Literature DB >> 7046656

CEA monitoring among patients in multi-institutional adjuvant G.I. therapy protocols.

G Steele, S Ellenberg, K Ramming, M O'Connell, C Moertel, H Lessner, H Bruckner, J Horton, P Schein, N Zamcheck, J Novak, E D Holyoke.   

Abstract

The Gastrointestinal Tumor Study Group (GITSG) has since 1975 included protocols for monitoring carcinoembryonic antigen (CEA) levels in its colorectal cancer adjuvant trials. Among the 563 patients on the colon cancer study (GI 6175) and the 207 patients on the rectal cancer study (GI 7175), one third had preoperative CEA determinations and more than 90% had some postoperative CEA monitoring. Colon cancer patients whose preoperative CEA was greater than 5 ng/ml had a greater probability of recurring than those whose values were lower (33% versus 18% recurrence with 21 months minimum follow-up; p < 0.05). The prognostic value of preoperative CEA was apparent only in patients with Dukes' C1 colon tumors. Preoperative CEA values were not of prognostic significance among the rectal adenocarcinoma patients. Although elevated levels of CEA after resection of either colon or rectum cancers were strongly associated with subsequent tumor recurrence, no single CEA value, arbitrarily defined as "elevated", provided an adequate screening test with both high sensitivity and high specificity. Postoperative CEA elevations were more strongly predictive of recurrence when part of a steadily rising trend. In the colon cancer study, the median monthly increase in CEA for disease-free patients was estimated to be zero, and for the relapsed patients 5.8%. The corresponding estimates for patients on the rectal cancer protocol were zero and 7.8%. Only 36 of the 344 disease-free patients on the colon protocol and 14 of the 94 disease-free patients on the rectal protocol (15%) exhibited a rate of increase of CEA as high as 3% per month over the entire period of observation. Two thirds of the relapsed patients on both studies showed a rate of increase this high or higher. The patterns of CEA rise in individual patients were quite varied, however, and monthly rates of increase as established in our study are not to be used as guidelines in patient management.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7046656      PMCID: PMC1352471          DOI: 10.1097/00000658-198208000-00008

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  12 in total

1.  A carcinoembryonic antigen standardization experiment for the conduct of multi-institutional clinical trials. Gastrointestinal Tumor Study Group.

Authors:  P T Lavin; N Zamcheck; E D Holyoke
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

2.  Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer.

Authors:  H J Wanebo; B Rao; C M Pinsky; R G Hoffman; M Stearns; M K Schwartz; H F Oettgen
Journal:  N Engl J Med       Date:  1978-08-31       Impact factor: 91.245

3.  Results of CEA-initiated second-look surgery for recurrent colorectal cancer.

Authors:  G Steele; N Zamcheck; R Wilson; R Mayer; J Lokich; P Rau; J Maltz
Journal:  Am J Surg       Date:  1980-04       Impact factor: 2.565

4.  Carcinoembryonic antigen (CEA) as a prognostic and monitoring test in clinically complete resection of colorectal carcinoma.

Authors:  M A Herrera; T M Chu; E D Holyoke
Journal:  Ann Surg       Date:  1976-01       Impact factor: 12.969

5.  Carcinoembryonic antigen test for recurrent colorectal carcinoma. Inadequacy for early detection.

Authors:  C G Moertel; A J Schutt; V L Go
Journal:  JAMA       Date:  1978-03-13       Impact factor: 56.272

6.  The use of preoperative plasma CEA levels for the Stratification of patients after curative resection of colorectal cancers.

Authors:  R Goslin; G Steele; J Macintyre; R Mayer; P Sugarbaker; K Cleghorn; R Wilson; N Zamcheck
Journal:  Ann Surg       Date:  1980-12       Impact factor: 12.969

7.  Use of CEA as an indicator of early recurrence and as a guide to a selected second-look procedure in patients with colorectal cancer.

Authors:  J H Wanebo; M Stearns; M K Schwartz
Journal:  Ann Surg       Date:  1978-10       Impact factor: 12.969

8.  The use of CEA as an early indicator for gastrointestinal tumor recurrence and second-look procedures.

Authors:  E W Martin; K K James; P E Hurtubise; P Catalano; J P Minton
Journal:  Cancer       Date:  1977-02       Impact factor: 6.860

9.  The use and limitations of serial plasma carcinoembryonic antigen (CEA) levels as a monitor of changing metastatic liver tumor volume in patients receiving chemotherapy.

Authors:  B R Bronstein; G D Steele; W Ensminger; W D Kaplan; M S Lowenstein; R E Wilson; J Forman; N Zamcheck
Journal:  Cancer       Date:  1980-07-15       Impact factor: 6.860

10.  The use of serial CEA determinations to predict recurrence of colon cancer and when to do a second-look operation.

Authors:  J P Minton; E W Martin
Journal:  Cancer       Date:  1978-09       Impact factor: 6.860

View more
  27 in total

1.  Surgical resection for colorectal hepatic metastases.

Authors:  G F Coppa
Journal:  Bull N Y Acad Med       Date:  1990 May-Jun

2.  Symposium: The management of recurrent colorectal cancer.

Authors:  F F Attiyeh; H Ellis; M Killingback; G D Oates; P F Schofield; H J Staab; G Steele; P H Sugarbaker
Journal:  Int J Colorectal Dis       Date:  1986-07       Impact factor: 2.571

3.  Carcinoembryonic antigen and carbohydrate antigen 19-9 are prognostic predictors of colorectal cancer with unresectable liver metastasis.

Authors:  Yoshinobu Mitsuyama; Hiroaki Shiba; Koichiro Haruki; Yuki Fujiwara; Kenei Furukawa; Tomonori Iida; Takenori Hayashi; Masaichi Ogawa; Yuichi Ishida; Takeyuki Misawa; Hideyuki Kashiwagi; Katsuhiko Yanaga
Journal:  Oncol Lett       Date:  2012-01-18       Impact factor: 2.967

4.  The prognostic value of the modifications of the Dukes' C class of colorectal cancer. An analysis of the NSABP clinical trials.

Authors:  N Wolmark; B Fisher; H S Wieand
Journal:  Ann Surg       Date:  1986-02       Impact factor: 12.969

5.  A prospective evaluation of serum carcinoembryonic antigen (CEA) levels in the management of colorectal carcinoma.

Authors:  J Boey; H C Cheung; C K Lai; J Wong
Journal:  World J Surg       Date:  1984-06       Impact factor: 3.352

6.  The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer. Results from NSABP (National Surgical Adjuvant Breast and Bowel Project) clinical trials.

Authors:  N Wolmark; B Fisher; H S Wieand; R S Henry; H Lerner; S Legault-Poisson; P J Deckers; N Dimitrov; P H Gordon; P Jochimsen
Journal:  Ann Surg       Date:  1984-04       Impact factor: 12.969

7.  Hepatic resection for metastatic colon and rectal cancer. An evaluation of preoperative and postoperative factors.

Authors:  G F Coppa; K Eng; J H Ranson; T H Gouge; S A Localio
Journal:  Ann Surg       Date:  1985-08       Impact factor: 12.969

8.  Serum CEA in the follow-up of colorectal carcinoma: experience in a district general hospital.

Authors:  T G Allen-Mersh
Journal:  Ann R Coll Surg Engl       Date:  1984-01       Impact factor: 1.891

9.  Predictive Value of CEA for Survival in Stage I Rectal Cancer: a Population-Based Propensity Score-Matched Analysis.

Authors:  Ignazio Tarantino; Rene Warschkow; Bruno M Schmied; Ulrich Güller; Markus Mieth; Thomas Cerny; Markus W Büchler; Alexis Ulrich
Journal:  J Gastrointest Surg       Date:  2016-04-11       Impact factor: 3.452

10.  Local recurrence after curative resection in patients with colon and rectal cancers.

Authors:  H R Yun; L J Lee; J H Park; Y K Cho; Y B Cho; W Y Lee; H C Kim; H K Chun; S H Yun
Journal:  Int J Colorectal Dis       Date:  2008-08-08       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.